A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Stomach NeoplasmsCancer of StomachCancer of the StomachGastric CancerGastric Neoplasms

Interventions

DRUG

ASLAN001

ASLAN001 500mg BID

Trial Locations (2)

Seoul National University Hospital, Bundang

Seoul National University Hospital, Seoul